Nemolizumab (Nemluvio)

Canada’s Drug Agency (CDA-AMC) recommends that Nemluvio should be reimbursed by public drug plans for the treatment of patients aged 12 years and older with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable if certain conditions are met. Nemluvio should only be covered to treat patients aged 12 years and older with moderate to severe AD, provided that Nemluvio is covered in a similar way to other advanced systemic therapies (i.e., biologics and Janus kinase [JAK] inhibitors) currently reimbursed by public drug plans for the treatment of moderate to severe AD. In addition to following the pre-existing criteria for other advanced systemic therapies, Nemluvio should not be used in combination with other advanced systemic therapies. Nemluvio should only be reimbursed if the cost is reduced such that the total treatment cost of Nemluvio does not exceed the total treatment cost of the least costly advanced therapies reimbursed for moderate to severe AD.